Table 1.
Currently clinically targetable Immune Checkpoint and future candidates.
| IC | Binding Partners Expressed Respectively on |
Role | Targetability |
|---|---|---|---|
| PD-1—PD-L1 | T cells—tumor cells | Negative IC | Currently targetable |
| CTLA-4—B7 | T cells—tumor cells | Negative IC | Currently targetable |
| TIM-3—Galectin-9 | T cells—tumor cells | Negative IC | Still not targetable |
| LAG3—class II MHC/galectin-3/LSECtin | T cells—tumor cells | Negative IC | Still not targetable |
| VISTA—Still unknown | T cells | Negative IC | Still not targetable |
| OX40—OX40L | T cells—APCs | Positive IC | Still not targetable |
| GITR—GITRL | T cells—APCs | Positive IC | Still not targetable |